Should You Buy Gilead Now That It's Acquiring Immunomedics?
Many investors have long hoped that Gilead Sciences (NASDAQ: GILD) would use its massive cash stockpile to fund a major acquisition. That hope is now being fulfilled.
Gilead announced on Sunday that it plans to acquire Immunomedics (NASDAQ: IMMU) for around $21 billion. At nearly twice the size of its $11.9 billion purchase of Kite Pharma in 2017, it's by far the biggest deal in the company's history. Should you buy the biotech stock now that it's acquiring Immunomedics?
Image source: Getty Images.
Source Fool.com
